Since the first FDA approval for weight loss, GLP-1 receptor agonists are in the news as new blockbuster drugs.
As of today, neither Novo Nordisk's Ozempic / Wegovy (Semaglutid), nor Eli Lilly's Mounjaro / Tirzepatid are projected to generate more sales than Merck's Keytruda (Pembrolizumab, a checkpoint inhibitor used in tumor therapy).
Will the newly approved GLP-1 agonists live up to the hype and sell even better than expected, becoming the new bestselling drugs on the global market?
This market will resolve YES if a GLP-1 agonist is the best-selling drug in 2023 (new sales) per reliable company or media reports.
Related questions
🏅 Top traders
| # | Name | Total profit |
|---|---|---|
| 1 | Ṁ137 | |
| 2 | Ṁ83 | |
| 3 | Ṁ8 | |
| 4 | Ṁ8 | |
| 5 | Ṁ6 |
⚠Unreceptive to pings ; AFK Creator
@traders This seems like it will resolve YES or N/A ; I believe I will be able to find the conclusive data through subscription services I use, but may take a few days.
Does anyone have anything public that would be able to resolve this quicker for a YES or NO resolution?
@habakuk Please let me know if you need to extend the market or if you are ready to resolve and if you have more proof. Thank you.
@habakuk Did you intend to have this close at end of 2023? The data for this officially usually is not released until around August, it could be sooner, but based on 10 years the average is August.
It is already pretty known that it will be a GLP-1 most likely.
Did you want to extend the market?
This is the projected 2024 GLOBAL sales.
@SirCryptomind All sources found still say a GLP-1 is #1 in the US and Global for 2023 expected sales. This is due to the drop off of covid, so the previous #1 and #3 were covid treatments, and those dropped down.